{
    "nct_id": "NCT04464226",
    "official_title": "An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies",
    "inclusion_criteria": "* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n* Participants enrolled in any Bayer-sponsored darolutamide feeder study at the time of study closure or primary completion, who are currently receiving darolutamide and are experiencing clinical benefit from treatment.\n* Participants who have not met any treatment discontinuation criteria in the feeder study protocol.\n* Willingness to continue practicing acceptable methods of birth control during the study.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participant is unable to comply with the requirements of the study.\n* Negative benefit/ risk ratio as determined by the investigator.\n* Meet any criteria for treatment discontinuation of the feeder study the participant is coming from.",
    "miscellaneous_criteria": ""
}